Publication:

Glucagon-like peptide-1 analog in the treatment of metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children with obesity. No pharmacological therapies are currently approved specifically for paediatric MASLD. A 12-year-old boy with obesity presented with persistent hypertransaminasemia and ultrasound-confirmed hepatic steatosis. After lifestyle interventions failed to improve liver enzymes, a glucagon-like peptide 1 (GLP-1) analog was initiated and titrated to 1.8 mg/day. Six months later, transaminases improved, accompanied by a 4 kg weight loss. After one year, liver enzymes normalized without adverse effects. This case supports the potential role of GLP-1 analog as a therapeutic option for paediatric MASLD, warranting further study.